Liver fibrosis in metabolic dysfunction-associated steatotic liver disease: epidemiology, risk stratification and therapeutics - Poll - MDSpire
Coming Soon: Introducing MDSpire News. Learn more
Conexiant’s news site is now MDSpire News. Learn more

Fibrosis of the Liver in Metabolic Dysfunction-Related Steatotic Liver Disease: A Review of Epidemiology, Risk Assessment, and Treatment Options

  • By

  • Fuliang Li

  • Hongmei Li

  • Dulguun Juramt

  • Kai Kou

  • Frank Tacke

  • Lanlan Chen

  • July 2, 2026

Share

Original Source(s)

Liver fibrosis in metabolic dysfunction-associated steatotic liver disease: epidemiology, risk stratification and therapeutics

  • by Fuliang Li, Hongmei Li, Dulguun Juramt, Kai Kou, Frank Tacke, Lanlan Chen

  • July 2, 2026

Related Content

Association between metabolic risk factors and hepatocellular carcinoma: a systematic review and meta-analysis of cohort studies

NLR inflammasome pathways: key targets for pathogenesis and therapy of metabolic diseases

Survodutide in adults with obesity and metabolic dysfunction-associated steatotic liver disease: SYNCHRONIZE-MASLD, a randomized, double-blind, placebo-controlled phase 3 trial